ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Trial ID or NCT#

NCT01834937

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.

Official Title

A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Pejman Ghanouni, MD, PhD
Pejman Ghanouni, MD, PhD
Radiologist
Associate Professor of Radiology (Body MRI) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov